Purpose: Debridement, antibiotics, and implant retention (DAIR) is an established treatment modality in periprosthetic joint infections (PJIs), but success rates vary. This study compared the success of DAIR for PJIs after a total hip arthroplasty (THA), with or without local antibiotic delivery with CaSO as the carrier material. Methods: A retrospective review of DAIR for PJIs after THA performed between 2010 and 2018, including 41 patients is conducted. A total of 27 patients were treated by DAIR with local antibiotics with CaSO as the carrier material, and 14 patients were treated by a standard DAIR. The endpoints were treatment failure, defined as the need for a reoperation, either a second DAIR or a prosthesis removal or exchange due to persistent or recurrent infection, the initiation of a long-term suppressive antibiotic treatment, or death related to infection. Results: Considering any reoperation as an outcome, 11 of 14 cases treated without AB-CaSO (79 %) and 4 of the 27 cases treated with AB-CaSO failed (15 %). Considering revision as an outcome, 9 out of 14 cases treated without AB-CaSO (64 %) and 4 of the 27 cases treated with AB-CaSO (15 %) failed. A Kaplan–Meier survival analysis showed that local antibiotic delivery with CaSO as the carrier material led to a significantly longer infection-free survival, considering any surgical revision (; hazard ratio 8.9 (95 % CI 2.8–28.2)) or revision with component exchange (; hazard ratio 5.6 (95 % CI 1.7–18.2)) as the endpoint. Conclusion: The addition of local antibiotics with CaSO as the carrier material to DAIR for PJIs after THA significantly increases success rates, such as infection-free survival, any reoperation, and revision with component exchange in particular.